PR95099

LONDON and NEW YORK, March 24, 2022 /PRNewswire=KYODO JBN/ --

Huma acquires AstraZeneca’s digital health platform AMAZE(TM) and AstraZeneca

becomes a shareholder of Huma

Huma Therapeutics Limited [https://www.huma.com/], a global digital health

technology company advancing digital-first care delivery and research to help

people live longer, fuller lives, today announced a new partnership with

AstraZeneca to scale innovation      for digital health. This agreement follows

prior use cases executed between Huma and AstraZeneca, reflecting a shared

ambition to improve clinical outcomes through digital health solutions to

bridge the gap between patients and clinicians.

As part of this partnership, Huma and AstraZeneca will launch Software as a

Medical Device (SaMD) companion apps targeted at several therapeutic areas and

will partner to help accelerate adoption of decentralized clinical trials.

These will build on Huma’s proven technologies which already power

digital-first care serving more than 1.8 million active patient users across

more than 3,000 hospitals and clinics. Huma’s technologies are designed to

connect with clinical workflows, allowing for more efficient care delivery.

“Our track record of scaling innovation has set the stage for this important

partnership with one of the world’s largest biopharmaceutical

companies. I am excited to have AstraZeneca’s support to build upon our

10-year experience of delivering digital-first solutions across healthcare and

clinical trials,” said Dan Vahdat, CEO of Huma. “The combination of pioneering

leadership, global-reach, deep medical knowledge and digital innovation will

enable our award-winning(1) platform to help more people live longer, fuller

lives."

"This collaboration marks an important moment as it is a first for AstraZeneca

in the digital health space as well as in the industry for chronic diseases and

SaMDs in support of different treatments,” said Karan Arora, Chief Commercial

Digital Officer, AstraZeneca. “With Huma, we are accelerating AstraZeneca’s

ambition to achieve earlier diagnosis and treatment for patients with chronic

diseases so they can lead better, more fulfilling lives.”

Ninety-five percent of care for chronic conditions happens outside the clinical

setting(2), highlighting the need for more digital-first care. AstraZeneca has

invested in the development and clinical validation of the patient centered

AMAZE chronic disease management platform to improve the care of patients.

AstraZeneca has used the AMAZE platform to conduct clinical studies at leading

U.S. academic medical centers with the goals of improving patient engagement,

care-team communication and clinical outcomes while reducing healthcare costs.

The collaboration with Huma will leverage the strong foundations and early

success of AMAZETM to accelerate digital-first care across therapeutic areas

and launch SaMDs.

"We are very excited to be working more closely with Huma across our digital

health initiatives,” said Ruud Dobber, Executive Vice President and President,

Biopharmaceuticals Business Unit, AstraZeneca. “We believe digital can expand

access to healthcare, advance clinical research, and identify existing gaps in

care. Additionally, with this innovative partnership, we will bring a

combination of technology along with expertise in research and drug development

to global decentralized clinical trials advancing the science of right patient,

right therapy, right time.”

About Huma

Huma Therapeutics is a global digital health technology company that advances

digital-first care delivery and research to help people live longer, fuller

lives. Huma’s award-winning modular platforms are used by more than 3,000

hospitals and clinics, with 1.8 million active users. Huma’s offering works

across different disease areas and powers:

- ‘Hospitals at Home’

- Software as a Medical Device (SaMD) solutions

- DCT platform to support digital or hybrid studies

Huma’s platform has been shown to almost double clinical capacity3, reduce

readmissions by over a third, enable better diversity, participant retention

and protocol adherence, whilst allowing trials to run within weeks. Please

visit www.huma.com and follow us on LinkedIn at Huma

[https://www.linkedin.com/company/humaforhealth/].

References

1. Huma Therapeutics wins Prix Galien USA 2021 award

[https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fhuma.com%2Fth

oughtpiece%2Fprixgalienaward&data=04%7C01%7Crelease%40prnewswire.co.uk%7Cc70ed8e

d5bf8483c4c7a08da0b593c36%7C887bf9ee3c824b88bcb280d5e169b99b%7C1%7C0%7C637834775

135487916%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik

1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=DdIRB17F8Bt35gT%2BU9s4yo3POkSAKuBT3i31y8prx2c%

3D&reserved=0] for Best Digital Health Product

2. American Academy of Family Physicians:

https://www.aafp.org/fpm/2000/0300/p47.html

3. NHSX report:

nhsx.nhs.uk/covid-19-response/technology-nhs/huma-medopad-evaluation-remote-digi

tal-care-platform/ The full report is available on request.

Logo - https://mma.prnewswire.com/media/1427908/Huma_Logo.jpg

Source: Huma